THAR insider filing: Director now holds 55,000 derivative secs
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Tharimmune, Inc. (THAR) reported insider activity on a Form 4. Director James Liddy received a stock option grant for 5,000 derivative securities on 11/03/2025 at an exercise price of $3.075 per share. The options are exercisable on 11/03/2025 and expire on 11/03/2035, covering underlying Common Stock (5,000 shares). Following this transaction, Liddy beneficially owns 55,000 derivative securities. The ownership form is reported as Direct (D).
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Liddy James Gordon
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 5,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option — 55,000 shares (Direct)
Footnotes (1)
FAQ
What did THAR director James Liddy report on Form 4?
A grant of 5,000 stock options exercisable into Common Stock at $3.075 per share.
What is the exercise price and date for the THAR options?
The options have an exercise price of $3.075 and are exercisable on 11/03/2025.
When do the reported THAR stock options expire?
The options expire on 11/03/2035.
How many derivative securities does James Liddy hold after the transaction?
He beneficially owns 55,000 derivative securities following the reported transaction.
What was the Form 4 transaction code for the THAR option grant?
The transaction code was A, indicating an award/grant.
What is the ownership form for the reported THAR securities?
Ownership is reported as Direct (D).